ClinicalTrials.gg
Not yet recruitingNCT07502729Updated Mar 31, 2026

Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding

An observational study in Portal Hypertension, Gastroesophageal Varices Hemorrhage and Gastric Varices, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Primary conditionEsophageal and Gastric VaricesRegistry: Hypertension, PortalReclassifiedWhy we changed it
Registry
Hypertension, Portal — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal and Gastric Varices
Why
  1. The study's listed conditions name Esophageal and Gastric Varices, a narrower term within Hypertension, Portal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shanghai Zhongshan Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,066
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital — 2 open to participants now, 2 under way, none of them phase 3. Esophageal and Gastric Varices · Shanghai Zhongshan Hospital.

Started
2026
the only one that year
Observational
4 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, this one is the only one that started in 2026, is one of 4 observational ones, and was the 13th registered.

Esophageal and Gastric Varices

150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.

Browse Esophageal and Gastric Varices studies →

Open to participants now

2 of the 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 20 Esophageal and Gastric Varices studies recruiting now, 13 (65%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Esophageal and Gastric Varices by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.

03

Conditions studied

  • Portal Hypertension
  • Gastroesophageal Varices Hemorrhage
  • Gastric Varices
  • Esophageal Varices

Browse trials for

04

In context

Esophageal and Gastric Varices Reclassified

150 studies on the registry are indexed under Esophageal and Gastric Varices; 39 are open to participants now.

This study's planned enrollment of 1,066 is above the median of 130 across 44 observational studies indexed under Esophageal and Gastric Varices.

Browse Esophageal and Gastric Varices studies →

Lead sponsor

Shanghai Zhongshan Hospital is the lead sponsor of 654 studies on the registry; 293 are open to participants now.

Compared within Esophageal and Gastric Varices, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Portal. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Enrolled were patients who presented to Zhongshan Hospital, Fudan University and other study centers due to esophagogastric variceal bleeding secondary to portal hypertension between December 2025 and December 2026.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted due to gastrointestinal bleeding and clinically diagnosed with portal hypertension
  • Underwent imaging examinations and gastroscopy within one week after admission
  • Gastroscopy revealed the presence of esophageal and/or gastric varices
  • Age over 18 years

Exclusion criteria

Exclusion Criteria:

  • Previous history of liver transplantation
  • Imaging or gastroscopy findings indicated ulcers or other causes of gastrointestinal bleeding
  • Concurrent severe life-threatening diseases involving the circulatory, hematological, or respiratory systems
  • Difficulty in follow-up, or lack of essential medical history information, imaging data, or other necessary records
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,066 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • TIPS treatment group

    The patient underwent Transjugular Intrahepatic Portosystemic Shunt (TIPS) after admission

  • Endoscopic treatment group

    The patient only received endoscopic treatment after admission.

07

What researchers measure

Primary outcomes

  1. 1-year gastrointestinal rebleeding rate

    Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)

    Time frame: 1 year after the treatment.

Secondary outcomes

  1. 2-month and 6-month gastrointestinal rebleeding rates

    Time from initial variceal bleeding treated with endoscopy or TIPS to recurrent variceal rupture and bleeding due to portal hypertension (at least 120 hours)

    Time frame: 2 months and 6 months after the treatment

  2. Indicators in the Child-Pugh classification include the progression of ascites and changes in bilirubin levels.

    Depth of abdominal fluid dark area detected by abdominal ultrasound; changes in serum bilirubin levels in liver function tests.

    Time frame: 1, 2, 6, and 12 months after the treatment.

  3. Changes of portal vein thrombosis

    Evaluate the occurrence, recanalization, and other changes in thrombosis every 6 months using portal CTA and ultrasound.

    Time frame: 6 and 12 months after the treatment.

  4. Liver cancer

    Hepatocellular carcinoma or cholangiocarcinoma

    Time frame: Up to 12 months after the treatment.

  5. Liver transplantation

    Based on comprehensive clinical evaluation, liver transplantation is required.

    Time frame: Up to 12 months after the treatment.

  6. Variceal bleeding-related mortality

    During the follow-up period, deaths caused by variceal rupture and bleeding that occurred within 6 weeks after the bleeding episode and were clearly related to the bleeding, including hemorrhagic shock and multiple organ failure.

    Time frame: Up to 12 months after the treatment.

  7. Liver-related mortality

    Deaths resulting from variceal rupture and bleeding, liver failure, hepatic encephalopathy, infection, hepatorenal syndrome, etc., excluding deaths due to extrahepatic causes, including: accidental death, cardiovascular events, and deaths caused by other systemic cancers.

    Time frame: Up to 12 months after the treatment.

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 31, 2026
StartEst.
Mar 17, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07502729
Collaborators
RenJi Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, Third Affiliated Hospital, Sun Yat-Sen University, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Nanchang University, Shanghai East Hospital, Shanghai Changzheng Hospital, Second Military Medical University, The General Hospital of Northern Theater Command
Responsible party
Shiyao Chen (Professor, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Mar 31, 2026
Start date
Mar 17, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 31, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion